Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYMPHONY-1: HTD1801 in Type 2 Diabetes Mellitus
NCT06350890Phase 3Completed
- Sponsor
- HighTide Therapeutics, Inc.
- Start
- Nov 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing HTD1801 1000 mg BID with Placebo BID (2 arms). Primary endpoint: Mean Change in HbA1c at 24 weeks. Started Nov 2023; status: completed.
02
Drugs
berberine ursodeoxycholate
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06350890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06350890.